13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002050194
Total reported value
$509.7M
$509.7M
27 檔
26.9%
As reported in its official Q4 2025 Form 13F filing, Spruce Street Capital LP's tracked investment portfolio stood at $509.7M with 27 total positions.
During Q4 2025, Spruce Street Capital LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CDTX | Cidara Therapeutics Inc | Stock-Other | 16.95% | — | — | |
| 2 | RLAY | Relay Therapeutics Inc | Stock-Other | 8.34% | +3.81% | — | |
| 3 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 7.40% | +0.67% | — | |
| 4 | RLMD | Relmada Therapeutics Inc | Stock-Other | 6.52% | -1.66% | — | |
| 5 | PCVX | Vaxcyte Inc | Stock-Other | 6.10% | +0.06% | — | |
| 6 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 5.93% | +2.71% | — | |
| 7 | EYPT | Eyepoint Inc | Stock-Other | 5.93% | — | — | |
| 8 | SVRA | Savara Inc | Stock-Other | 4.80% | -0.27% | — | |
| 9 | ERAS | Erasca Inc | Stock-Other | 4.78% | -0.12% | — | |
| 10 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 4.05% | -0.74% | — | |
| 11 | SRZN | Surrozen Inc | Stock-Other | 3.23% | -0.83% | — | |
| 12 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.14% | — | — | |
| 13 | SABS | Sab Biotherapeutics Inc | Stock-Other | 2.72% | -0.34% | — | |
| 14 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 2.43% | -0.02% | — | |
| 15 | ELVN | Enliven Therapeutics Inc | Stock-Other | 2.27% | +0.18% | — | |
| 16 | NERV | Minerva Neurosciences Inc | Stock-Other | 2.20% | -0.60% | — | |
| 17 | ABVX | Abivax Sa-adr | Stock-Other | 2.19% | — | — | |
| 18 | HELP | Cybin Inc | Stock-Other | 2.08% | — | — | |
| 19 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 2.07% | -4.34% | EXIT | |
| 20 | ENTA | Enanta Pharmaceuticals Inc | Stock-Other | 2.03% | +0.28% | — | |
| 21 | ANRO | Alto Neuroscience Inc | Stock-Other | 1.31% | +0.01% | — | |
| 22 | LONA | Leonabio Inc | Stock-Other | 0.98% | -0.21% | — | |
| 23 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.64% | -4.68% | EXIT | |
| 24 | ALEC | Alector Inc | Stock-Other | 0.58% | -0.26% | — | |
| 25 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.57% | -0.43% | — | |
| 26 | IPSC | Century Therapeutics Inc | Stock-Other | 0.47% | -0.26% | — | |
| 27 | STRO | Sutro Biopharma Inc | Stock-Other | 0.29% | — | — |
According to official SEC Form 13F filings, Spruce Street Capital LP reported a total U.S. public equity portfolio value of $509.7M across 27 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CDTX, RLAY, LBRX) accounted for 26.9% of total reported equity market value during Q4 2025.
During Q4 2025, Spruce Street Capital LP's top holdings by market value included CDTX (16.9%)、RLAY (8.3%)、LBRX (7.4%). The largest single position, CDTX, represented 16.9% of total portfolio value.
In Q4 2025, Spruce Street Capital LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.